Covalent inhibition has become an increasingly important strategy in modern medicinal chemistry and drug discovery. Although covalent drugs were historically associated with non-specific reactivity and potential toxicity, advances in medicinal chemistry have enabled the development of highly selective compounds with substantial clinical success. Numerous covalent drugs have been approved for the treatment of cancer and other diseases, while many additional compounds are undergoing clinical evaluation. The mechanism of action of covalent inhibitors involves the selective irreversible or reversible covalent modification of nucleophilic amino acid residues within target proteins, most commonly cysteine residues located in binding sites, following an initial noncovalent recognition step. As a result, modern covalent drug design requires careful optimisation of electrophile reactivity to achieve an appropriate balance between potency, selectivity, and safety. Among currently used electrophilic warheads, acrylamides represent the most common class in approved drugs and clinical candidates. Other important reactive motifs include aldehydes, α-ketoamides, nitriles, vinyl sulfones, boronic acids, and sulfonyl fluorides. The reactivity and selectivity of these moieties can be fine-tuned through structural and electronic modifications, making synthetic organic chemistry a key element of covalent drug discovery. Continued advances in warhead design, structure-based optimization, and proteomic methods for identifying new targets are expected to further broaden the therapeutic potential and clinical applications of this approach.